PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Research spotlight: Combination therapy shows promise for overcoming treatment resistance in glioblastoma

Researchers have identified a previously unknown determinant of resistance to immune checkpoint blockers in glioblastoma and a strategy to overcome it.

2025-09-18
(Press-News.org) Rakesh Jain, PhD, director of the Edwin Steele Laboratories for Tumor Biology in the Department of Radiation Oncology at Massachusetts General Hospital and Andrew Werk Professor of Radiation Oncology at Harvard Medical School, is senior and corresponding author of a new paper in PNAS, “Wnt Inhibition Alleviates Resistance to Anti-PD1 Therapy and Improves Anti-Tumor Immunity in Glioblastoma."

Q: How would you summarize your study for a lay audience?

Brain tumor patients with glioblastoma (GBM) face extremely limited treatment options and show poor responses to current immunotherapies. New treatment strategies are desperately needed.

Wnt signaling is a crucial cell communication process that regulates various aspects of stem cell behavior. It is also pivotal in the generation of GBM and contributes to treatment resistance.

In this new study, we identify Wnt7b, which is highly expressed in GBM patients, as a previously unknown determinant of resistance to immune checkpoint blockers.

Our findings reveal that targeting the Wnt7b/β-catenin pathway can sensitize stem-cell rich GBM to immune checkpoint blockade, offering a promising new therapeutic avenue.

We also demonstrate the potential of a porcupine inhibitor, WNT974, which has been shown to be safe in a phase I trial in patients with extracranial tumors, to synergize with anti-PD1 therapy by alleviating immunosuppressive mechanisms and enhancing anti-tumor immunity.

These results support the rationale for personalized clinical trials of combination WNT974/anti-PD1 therapy in glioblastoma patients with elevated Wnt7b/β-catenin signaling, aiming to overcome resistance to immunotherapy.

Q: What question were you investigating?

Glioblastoma (GBM) is a deadly brain cancer. Current treatments, including a type of immunotherapy called anti-PD1, don’t work well for most patients. We are trying to figure out why—and how to fix it.

Q: What methods or approach did you use?

We found that a molecule called Wnt7b is very active in GBM tumors. This molecule seems to help cancer suppress the immune system, making treatments like anti-PD1 less effective.

We tested a drug called WNT974, which blocks Wnt signaling, as a combination therapy along with anti-PD1 immune checkpoint therapy.

Q: What did you find?

When we gave this drug to mouse models of GBM alongside anti-PD1 therapy, the results were promising—the tumors shrank, the mice lived longer, and some mice did not develop tumors again.

A closer look revealed that the combination therapy was effective in:

Waking up the immune system by helping special cells (called dendritic cells) make the tumor more visible Boosting killer T cells that attack the tumor Reducing suppressor cells that normally protect the tumor from immune attack Q: What are the implications?

GBM patients face extremely limited treatment options and poor responses to current immunotherapies. Our findings reveal that targeting the Wnt7b/β-catenin pathway can sensitize stem-cell rich GBM to immune checkpoint blockade, offering a promising new therapeutic avenue.

Q: What are the next steps?

These results support the rationale for personalized clinical trials in glioblastoma patients with elevated Wnt7b/β-catenin signaling, aiming to overcome resistance to immunotherapy.

Read the paper (opens external link in new tab)

Authorship: In addition to Jain, Mass General Brigham authors include Shanmugarajan Krishnan, Somin Lee, Zohreh Amoozgar, Sonu Subudhi, Ashwin Srinivasan Kumar, Jessica M. Posada, Neal Lindeman, Pinji Lei, Mark Duquette, Sophie Steinbuch, Marc Charabati, Peigen Huang, Patrik Andersson, Meenal Datta, Lance L. Munn and Dai Fukumura.

Paper cited: Krishnan, S., et al. “Wnt inhibition alleviates resistance to anti-PD1 therapy and improves anti-tumor immunity in glioblastoma.” PNAS. DOI: https://doi.org/10.1073/pnas.2414941122

Funding: This work was supported by grants from the National Institutes of Health and the National Foundation for Cancer Research, Jane’s Trust Foundation, Niles Albright Research Foundation and Harvard Ludwig Cancer Center, as well as Massachusetts General Hospital.

Disclosures: RKJ received consultant fees from SynDevRx; owns equity in Accurius, Enlight, and SynDevRx; served on the Board of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund; and received research grants Sanofi. LLM receives equity from Bayer and is a consultant for SimBiosys. No funding or reagents from these organizations were used in this study. SK is a current employee of and a holder of stock options with Agenus Inc. Other co-authors have no conflict of interest to declare.

Media contact

Alex Pantano

Senior Specialist, External Communications

apantano@mgb.org 781-439-8971

About Mass General Brigham

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.

END


ELSE PRESS RELEASES FROM THIS DATE:

University of Houston co-leads $25 million NIH-funded grant to study the delay of nearsightedness in children

2025-09-18
Key Takeaways  University of Houston College of Optometry professor is co-leading a national $25 million NIH-funded clinical trial to delay the development of myopia.  Researchers are testing whether low-concentrate atropine drops can delay onset of myopia in children.  The more nearsighted someone becomes, the greater their risk of sight-threatening complications later as an adult.  The University of Houston is co-leading a national study, the first of its kind in the United States, ...

NRG Oncology PREDICT-RT study completes patient accrual, tests individualized concurrent therapy and radiation for high-risk prostate cancer

2025-09-18
PHILADELPHIA, PA – The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed accrual and met its accrual milestone of 2,478 patients approximately two years earlier than the trial’s anticipated accrual completion date. “The incidence of men receiving high-risk prostate cancer diagnoses is on the increase in recent years. The PREDICT-RT study was designed to improve quality of life and outcomes for these patients while tailoring treatments to meet each individual’s needs based on their Decipher Prostate Genomic Classifier ...

Taking aim at nearsightedness in kids before it’s diagnosed

2025-09-18
COLUMBUS, Ohio – For the first time, researchers are leading a national study to see if the onset of nearsightedness can be delayed – and consequently reduced in magnitude over a lifetime – with the use of eyedrops in young children. Scientists at The Ohio State University and the University of Houston have received two grants from the National Institutes of Health totaling $25 million to test daily drops of atropine as a nearsightedness preventive therapy in children age 6-11 years old. “The more nearsightedness you have, the ...

With no prior training, dogs can infer how similar types of toys work, even when they don’t look alike

2025-09-18
As infants, humans naturally learn new words and their associations—like the fact that forks are related to bowls because both are used to consume food. In a study publishing in the Cell Press journal Current Biology on September 18, a team of animal behavior experts demonstrate that dogs can categorize objects by function, too. In a series of playful interactions with their owners, a group of Gifted Word Learner (GWL) dogs were able to distinguish between toys used for tugging versus fetching, even when the toys in question didn’t share any obvious physical ...

Three deadliest risk factors of a common liver disease identified in new study

2025-09-18
LOS ANGELES — More than a third of the world’s population is affected by metabolic dysfunction-associated steatotic liver disease, or MASLD, the most common chronic liver disease in the world.   MASLD occurs when fat builds up in the liver and is associated with one or more of five conditions: obesity, Type 2 diabetes, high blood pressure, high blood sugar and low HDL cholesterol, known as “good” cholesterol. These conditions are characterized as cardiometabolic risk ...

Dogs can extend word meanings to new objects based on function, not appearance

2025-09-18
BUDAPEST, Hungary — A new study publishing in Current Biology on September 18 by the Department of Ethology at Eötvös Loránd University reveals that dogs with a vocabulary of toy names—known as Gifted Word Learners—can extend learned labels to entirely new objects, not because the objects look similar, but because they are used in the same way. In humans, “label extension” is a cornerstone of early language development. In non-humans, until now, it had only been documented in few so-called language-trained individual animals, after years of intensive training in captivity. But ...

Palaeontology: South American amber deposit ‘abuzz’ with ancient insects

2025-09-18
The first amber deposits in South America containing preserved insects have been discovered in a quarry in Ecuador, reports a paper in Communications Earth & Environment. The finding provides a snapshot of a 112-million-year-old forest on the supercontinent Gondwana, and presents new possibilities for studying a currently little-known ancient ecosystem. Amber (fossilised tree resin) samples have a wide date range, with the earliest dated to 320 million years ago, but there is a notable increase in the number of samples in the fossil record between 120 million and 70 million years ago, during the Cretaceous era ...

Oral microbes linked to increased risk of pancreatic cancer

2025-09-18
Twenty-seven species of bacteria and fungi among the hundreds that live in people’s mouths have been collectively tied to a 3.5 times greater risk of developing pancreatic cancer, a study led by NYU Langone Health and its Perlmutter Cancer Center shows. Experts have long observed that those with poor oral health are more vulnerable to pancreatic cancer than those with healthier mouths. More recently, scientists have uncovered a mechanism that could help explain this connection, finding that bacteria can travel through swallowed saliva into the pancreas, an organ that helps with digestion. However, precisely which species may contribute to the condition ...

Soccer heading does most damage to brain area critical for cognition

2025-09-18
NEW YORK, NY (Sept. 18, 2025)--A brain imaging technique developed by Columbia researchers has identified areas in the brain’s cerebral cortex—just behind the forehead—that are most damaged by the repetitive impacts from heading a soccer ball. Their study also found that the damage leads to cognitive deficits seen in soccer players who head the ball frequently.   The study, published Sept. 18 in JAMA Network Open, was conducted in amateur adult soccer players from New York City.  “What’s ...

US faces rising death toll from wildfire smoke, study finds

2025-09-18
Wildfires burning across Canada and the Western United States are spewing smoke over millions of Americans – the latest examples of ashy haze becoming a regular experience, with health impacts far greater than scientists previously estimated.  Although wildfires have long been part of life in the Western U.S., warmer, drier conditions are fueling bigger blazes that occur more often and for longer. Smoke from these blazes is spreading farther and lingering longer than in the past. In a Sept. 18 study in Nature, Stanford University researchers estimate that continued global warming could lead ...

LAST 30 PRESS RELEASES:

Major review highlights latest evidence on real-time test for blood – clotting in childbirth emergencies

Inspired by bacteria’s defense strategies

Research spotlight: Combination therapy shows promise for overcoming treatment resistance in glioblastoma

University of Houston co-leads $25 million NIH-funded grant to study the delay of nearsightedness in children

NRG Oncology PREDICT-RT study completes patient accrual, tests individualized concurrent therapy and radiation for high-risk prostate cancer

Taking aim at nearsightedness in kids before it’s diagnosed

With no prior training, dogs can infer how similar types of toys work, even when they don’t look alike

Three deadliest risk factors of a common liver disease identified in new study

Dogs can extend word meanings to new objects based on function, not appearance

Palaeontology: South American amber deposit ‘abuzz’ with ancient insects

Oral microbes linked to increased risk of pancreatic cancer

Soccer heading does most damage to brain area critical for cognition

US faces rising death toll from wildfire smoke, study finds

Scenario projections of COVID-19 burden in the US, 2024-2025

Disparities by race and ethnicity in percutaneous coronary intervention

Glioblastoma cells “unstick” from their neighbors to become more deadly

Oral bacterial and fungal microbiome and subsequent risk for pancreatic cancer

New light on toxicity of Bluefin tuna

Menopause drug reduces hot flashes by more than 70%, international clinical trial finds

FGF21 muscle hormone associated with slow ALS progression and extended survival

Hitting the right note: The healing power of music therapy in the cardiac ICU

Cardiovascular disease risk rises in Mexico, despite improved cholesterol control

Flexible optical touch sensor simultaneously pinpoints pressure strength and location

Achalasia diagnosis simplified to AI plus X-ray

PolyU scholars pioneer smart and sustainable personal cooling technologies to address global extreme heat

NIH grant aims for childhood vaccine against HIV

Menstrual cycle and long COVID: A relation confirmed

WMO report on global water resources: 2024 was characterized by both extreme drought and intense rainfall

New findings explain how a mutation in a cancer-related gen causes pulmonary fibrosis

Thermal trigger

[Press-News.org] Research spotlight: Combination therapy shows promise for overcoming treatment resistance in glioblastoma
Researchers have identified a previously unknown determinant of resistance to immune checkpoint blockers in glioblastoma and a strategy to overcome it.